(Albany, USA) Asthma Pipeline Insight offers in-depth analysis of over 90+ companies and more than 100+ pipeline medications within the Asthma treatment landscape.
DelveInsight’s ‘Asthma Pipeline Insight 2024’ report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain.
To know more about the Asthma pipeline report, click here @ Asthma Pipeline Analysis
Key Takeaways from the Asthma Pipeline Report
- DelveInsight’s asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment.
- Leading asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape.
- Emerging asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
- On February 2024, AstraZeneca announced results of a Prospective, Observational, Real-World Evidence Study (ASCENT): Asthma Control in Severe Asthma Patients Treated With Tezepelumab.
- On November 2023, Regeneron Pharmaceuticals announced results of a study whose aim is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
- On February 2024, AstraZeneca announced results of a Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.
- On November 2023, GlaxoSmithKline announced results of a 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
- In February 2023, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.
Request a sample and discover the recent advances in asthma drug treatment @ Asthma Treatment Market
Asthma Overview
Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections.
A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.
Find out more about drugs for asthma @ Asthma Therapies and Drugs
Asthma Pipeline Drugs mentioned in the report:
- MM09-MG01: Inmunotek S.L.
- BGF MDI: AstraZeneca
- GSK3511294: GlaxoSmithKline
- FP 025: Foresee Pharmaceuticals
- ADX-629: Aldeyra Therapeutics
- 610: Sunshine Guojian Pharmaceutical
- EDP1867: Evelo Biosciences, Inc.
- CM-326 : Keymed Biosciences
- 9MW1911: Mabwell (Shanghai) Bioscience Co., Ltd.
- Dapansutrile: Olatec Therapeutics
- LNR 125.38: Lanier Biotherapeutics
Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials and FDA Approval
Asthma Therapeutics Assessment
The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Asthma Pipeline Report
- Coverage: Global
- Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others.
- Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Therapeutic Assessment
Table of Contents
1. Asthma Pipeline Report Introduction
2. Asthma Pipeline Report Executive Summary
3. Asthma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Asthma Clinical Trial Therapeutics
6. Asthma Pipeline: Late Stage Products (Pre-registration)
7. Asthma Pipeline: Late Stage Products (Phase III)
7.1.BGF MDI: AstraZeneca
8. Asthma Pipeline: Mid Stage Products (Phase II)
8.1. GSK3511294: GlaxoSmithKline
9. Asthma Pipeline: Early Stage Products (Phase I)
9.1. CM-326: Keymed Biosciences
10. Asthma Pipeline Therapeutics Assessment
11. Inactive Products in the Asthma Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Asthma Companies
14. Key Products in the Asthma Pipeline
15. Asthma Unmet Needs
16. Asthma Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting